Media headlines about BioMarin Pharmaceutical (NASDAQ:BMRN) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. BioMarin Pharmaceutical earned a daily sentiment score of 0.10 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 47.4912508412406 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the media headlines that may have effected Accern’s rankings:
A number of research firms have issued reports on BMRN. Leerink Swann reiterated an “outperform” rating and set a $142.00 target price (up previously from $136.00) on shares of BioMarin Pharmaceutical in a report on Thursday, October 19th. SunTrust Banks set a $115.00 price objective on BioMarin Pharmaceutical and gave the company a “buy” rating in a report on Thursday, October 19th. Piper Jaffray Companies restated a “buy” rating and issued a $113.00 price objective on shares of BioMarin Pharmaceutical in a report on Thursday, September 21st. Wedbush upgraded BioMarin Pharmaceutical from a “neutral” rating to an “outperform” rating and set a $110.00 price objective for the company in a report on Thursday, December 14th. Finally, BidaskClub upgraded shares of BioMarin Pharmaceutical from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 16th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $112.32.
Shares of BioMarin Pharmaceutical (BMRN) opened at $90.22 on Friday. BioMarin Pharmaceutical has a one year low of $80.10 and a one year high of $100.51. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.81 and a current ratio of 4.91.
BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its earnings results on Thursday, October 26th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.06. The firm had revenue of $334.18 million for the quarter, compared to analysts’ expectations of $347.38 million. BioMarin Pharmaceutical had a negative net margin of 12.45% and a negative return on equity of 4.60%. The company’s revenue was up 19.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.02 earnings per share. equities analysts forecast that BioMarin Pharmaceutical will post -0.64 earnings per share for the current year.
In related news, EVP George Eric Davis sold 1,200 shares of the business’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $85.64, for a total value of $102,768.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Jean Jacques Bienaime sold 10,000 shares of the business’s stock in a transaction on Friday, January 5th. The shares were sold at an average price of $90.32, for a total transaction of $903,200.00. Following the completion of the transaction, the chief executive officer now owns 235,894 shares in the company, valued at approximately $21,305,946.08. The disclosure for this sale can be found here. In the last quarter, insiders have sold 60,750 shares of company stock worth $5,439,788. 1.85% of the stock is owned by company insiders.
COPYRIGHT VIOLATION WARNING: This report was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/14/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-biomarin-pharmaceutical-bmrn-stock-price.html.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.